Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma

References

• AdjeiAACalvertAHHanauskeARPemetrexed (ALIMTA), a novel multitargeted antifolate agent, is active alone and in combination in thoracic tumorsLung Cancer200029389
   Google Scholar
• BerghmansTPaesmansMLalamiYActivity of chemotherapy and immunotherapy on malignant mesothelioma:a systematic review of the literature with meta-analysisLung Cancer2002381112112399121
   PubMed Web of Science ®Google Scholar
• BoyerMJassemJAlALESymptoms and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesotheliomaLung Cancer200341S19
   Google Scholar
• British Thoracic SocietyStatement on malignant mesothelioma in the United KingdomThorax2001562506511254815
   PubMed Web of Science ®Google Scholar
• BuddeLSHannaNHPemetrexed (Alimta.:improving outcomes in malignant pleural mesotheliomaExpert Rev Anticancer Ther20044361815161435
   PubMedGoogle Scholar
• BunnCPaolettiPNiyikizaCVitamin B12 and folate reduce toxicity of Alimta(™) (pemetrexed disodium, LY231514, MTA., a novel antifolate/antimetabolite.Proc Am Soc Clin Oncol200120 abstr 300
   Google Scholar
• CeresoliGLZucaliPAFavarettoAGPhase II study of pemetrexed plus carboplatin in malignant pleural mesotheliomaJ Clin Oncol2006241443816549838
   PubMed Web of Science ®Google Scholar
• CurtinNJHughesANPemetrexed disodium, a novel antifolate with multiple targetsLancet Oncol2001229830611905785
   PubMed Web of Science ®Google Scholar
• Eli lilly and CompanyClinical Study Summary:Study H3E-MC-JMAP2004a
   Google Scholar
• Eli lilly and CompanyClinical Study Summary:Study H3E-MC-JMDR2004b
   Google Scholar
• EllisPDaviesAMEvansWKThe use of chemotherapy in patients with advanced malignant pleural mesothelioma:a systematic review and practice guidelineJ Thorac Oncol2006159160117409924
   PubMed Web of Science ®Google Scholar
• FavarettoAOverview on ongoing or planned clinical trials in EuropeLung Cancer200549Suppl 1S1172115950791
   PubMed Web of Science ®Google Scholar
• GatzemeierUPemetrexed in malignant pleural mesotheliomaOncology (Williston Park)200418263115655933
   PubMedGoogle Scholar
• GrallaRJHollenPJLiepaAMImproving quality of life in patients with malignant pleural mesothelioma:Results of the randomized pemetrexed + cisplatin vs cisplatin trial using the LCSS-meso instrument. ASCO2003
   Google Scholar
• GreenJDundarYDoddSPemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesotheliomaCochrane Database Syst Rev2007CD00557417253564
   PubMed Web of Science ®Google Scholar
• HazarikaMWhiteRMJohnsonJRFDA drug approval summaries:pemetrexed (Alimta)Oncologist20049482815477632
   PubMed Web of Science ®Google Scholar
• HazarikaMWhiteRMJrBoothBPPemetrexed in malignant pleural mesotheliomaClin Cancer Res2005119829215709163
   PubMed Web of Science ®Google Scholar
• HollenPJGrallaRJLiepaAMAdapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma:using the LCSS-Meso conceptual model for validationCancer20041015879515274072
   PubMed Web of Science ®Google Scholar
• HughesACalvertPAzzabiAPhase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesotheliomaJ Clin Oncol20022035334412177114
   PubMed Web of Science ®Google Scholar
• ManegoldCSymanowskiJGatzemeierUSecond-line (post-study. chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesotheliomaAnn Oncol200516923715824080
   PubMed Web of Science ®Google Scholar
• NakagawaKKudohSMatsuiKA phase I dose-finding study of pemetrexed supplemented with folic acid (FA. and vitamin B12 in Japanese patients with solid tumorsProc Am Soc Clin Oncol20032222
   Google Scholar
• NiyikizaCBakerSDSeitzDEHomocysteine and methylmalonic acid:markers to predict and avoid toxicity from pemetrexed therapyMol Cancer Ther200215455212479273
   PubMed Web of Science ®Google Scholar
• PaolettiPPistolesiMRusthovenJCorrelation of pulmonary function tests with best tumor response status:results from the phase III study of pemetrexed + cisplatin vs cisplatin in malignant pleural mesotheliomaProc Am Soc Clin Oncol200322659
   Google Scholar
• PearceHLAlice MillerMThe evolution of cancer research and drug discovery at Lilly Research LaboratoriesAdv Enzyme Regul2005452295516143373
   PubMedGoogle Scholar
• PistolesiMRusthovenJMalignant pleural mesothelioma:update, current management, and newer therapeutic strategiesChest200412613182915486399
   PubMed Web of Science ®Google Scholar
• ReckMGatzemeierUPemetrexed-cisplatin combination in mesotheliomaExpert Rev Anticancer Ther20055231715877521
   PubMed Web of Science ®Google Scholar
• RobinsonBWLakeRAAdvances in malignant mesotheliomaN Engl J Med2005353159160316221782
   PubMed Web of Science ®Google Scholar
• RobinsonBWMuskAWLakeRAMalignant mesotheliomaLancet200536639740816054941
   PubMed Web of Science ®Google Scholar
• ShepherdFADanceyJArnoldAPhase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma:a study of the National Cancer Institute of Canada Clinical Trials GroupCancer20019259560011505404
   PubMed Web of Science ®Google Scholar
• SteeleJPThe new front line treatment for malignant pleural mesothelioma?Thorax20035896712554885
   PubMed Web of Science ®Google Scholar
• SteeleJPKlabatsaAChemotherapy options and new advances in malignant pleural mesotheliomaAnn Oncol2005163455115677623
   PubMed Web of Science ®Google Scholar
• SugarbakerDJFloresRMJaklitschMTResection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma:results in 183 patientsJ Thorac Cardiovasc Surg19991175463 discussion 63–59869758
   PubMed Web of Science ®Google Scholar
• TeicherBAChenVShihCTreatment regimens including the multitargeted antifolate LY231514 in human tumor xenograftsClin Cancer Res2000610162310741729
   PubMed Web of Science ®Google Scholar
• ThodtmannRDepenbrockHDumezHClinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514. in combination with cisplatinJ Clin Oncol19991730091610506594
   PubMed Web of Science ®Google Scholar
• VogelzangNSymanowskiJRusthovenJLong-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs. cisplatin in patients with malignant pleural mesothelioma (MPM)Lung Cancer200549S230
   Web of Science ®Google Scholar
• VogelzangNJRusthovenJJSymanowskiJPhase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol20032126364412860938
   PubMed Web of Science ®Google Scholar
• WeillHHughesJMChurgAMChanging trends in US mesothelioma incidenceOccup Environ Med2004614384115090665
   PubMed Web of Science ®Google Scholar
• ZidarBLGreenSPierceHIA phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group StudyInvest New Drugs1988622363192388
   PubMed Web of Science ®Google Scholar